The importance of this study is determined by the hypothetical key role of dicarbonyl-modified LDL in the molecular mechanisms of vascular wall lesions in atherogenesis and the development of endothelium failure [5,6]. In addition, the clearance of MDA-modified human LDL was investigated as part of a clinical trial on cholesterol-lowering therapy in coronary heart disease (CHD) patients with the PCSK9 inhibitor evolocumab. The gene discussed is PCSK9; the disease is coronary artery disorder.